What Bedrocan does

Bedrocan International is a Netherlands-headquartered, privately held producer of standardised, pharmaceutical-grade medicinal cannabis founded in 1984 in Veendam. The company manufactures cannabis Active Pharmaceutical Ingredients (APIs) — dried flower (flos) and cut flos — across multiple proprietary chemovars with fixed THC:CBD ratios, including Bedrocan (22% THC), Bedrocan forte (25% THC), Bedropuur (20% THC), Bedrolina (14% CBD), Bedrobinol, Bediol, Bedrolite, and Bedica. Its core technology is a proprietary standardisation method built on stable plant genetics and vegetative propagation that prevents genetic drift, combined with automated indoor cultivation under strict environmental controls, gamma irradiation sterilisation, and the company's own GMCCP quality standard layered on top of EU-GACP. Bedrocan was the first cannabis company in the world to obtain EU-GMP certification.

The company serves four primary customer segments: (1) government health programmes, with exclusive supply to the Dutch Medicinal Cannabis Programme since 2003; (2) compounding pharmacies that prepare magistral cannabis oil preparations; (3) pharmaceutical manufacturers and drug developers sourcing cannabis APIs for product development and clinical research; and (4) healthcare professionals prescribing or dispensing cannabis-based therapy. Distribution is concentrated through exclusive channel partners — Medios AG for Germany (with planned expansion to Austria, Belgium, Italy, and Spain from 2027) and Novachem for Australia — with direct supply to pharmaceutical manufacturers globally. Production is anchored in two Netherlands facilities (combined 7,500 kg/year) and a new EU-GMP-certified Danish facility in Køge (2,300 kg/year, inaugurated 2025), with a reacquired Toronto facility entering Canadian production.

Revenue is generated through unit-priced B2B sales of cannabis APIs, wholesale flower, and — from 2026 — finished patient-facing formulations under the new Bedromed line (sublingual spray and oromucosal drops) and the Becanex PIEX 70% THC concentrate developed with Berlin-based Becanex. Pricing in the Netherlands is set by the Bureau Medicinale Cannabis at approximately €8/gram, with international pricing varying by country and distribution arrangement. The company has supplied over 15,000 kg of medicinal cannabis to German patients since exports began in 2008, reflecting a long-duration, contract-anchored revenue model with growing geographic and product-line diversification.

Name

Bedrocan

Legal name

Bedrocan International

Website

https://bedrocan.com

Company type

Private

Founded year

1984

Operating status

Operating

Headcount range

11–50 employees

Short description

Bedrocan is a Netherlands-headquartered EU-GMP-certified producer of standardised pharmaceutical-grade medicinal cannabis APIs and finished formulations, supplying government health programmes, compounding pharmacies, and pharmaceutical manufacturers across Europe, Australia, and Canada via proprietary standardisation methods and exclusive distribution partners.

Ownership category

akta.pro rank

Product category

Medicinal Cannabis API Manufacturing

NAICS

Drugs and Druggists' Sundries Merchant Wholesalers (424210), Pharmaceutical Preparation Manufacturing (325412)

SIC

Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Pharmaceutical Preparations (2834)

akta.pro primary industry

Adult-Use (Recreational) Cannabis Dispensaries (CRANAFAA)

akta.pro secondary industries

Cannabis Accessories & Smoke Shops (Pipes, Papers, Grinders) (CRANAHAG), Cannabis Accessories & Ancillary Product Delivery (Vapes, Papers, Devices) (CRANAGAJ), Medical Cannabis Dispensaries (CRANAFAB)

Keywords

• Medicinal cannabis
• Pharmaceutical cannabis API
• Cannabis flower production
• Standardized cannabinoid products
• Cannabis active pharmaceutical ingredient

Headquarters

HQ city

Veendam

HQ country

Netherlands

HQ region

Europe

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Supply Chain, Marketing or Sales

Revenue model

1. Cannabis API and Raw Material Sales: Bedrocan produces and sells standardised cannabis as Active Pharmaceutical Ingredients (APIs) and pharmaceutical raw materials to large and small drug developers, pharmaceutical manufacturers, and compounding pharmacies worldwide. Products are sold in various forms including flos (whole dried flower), cut flos (ground dried flower), and as inputs for extracts and formulations. The company also generates revenue from supplying the Dutch Medicinal Cannabis Programme exclusively since 2003.
2. Finished Cannabinoid Formulations (Bedromed): Bedrocan launched Bedromed, a new product line of standardised cannabinoid-based formulations including sublingual spray and oromucosal drops in various THC:CBD ratios, extending the company's API business into patient-friendly finished delivery formats.
3. Cannabis Concentrate for Compounding: Partnership with Becanex to launch Bedrocan flower as a 70% THC pharmaceutical-grade concentrate (Becanex PIEX Bedrocan 70% THC Concentrate) for compounding pharmacies, preserving the natural cannabinoid and terpene profile through proprietary extraction.

Pricing tiers

Go-to-market motion3 records

Distribution channels5 records

Marketing channels7 records

Core offering

Bedrocan produces and sells standardised, pharmaceutical-grade medicinal cannabis as Active Pharmaceutical Ingredients (APIs) in various chemovars with fixed THC:CBD ratios, supplied as dried flower (flos) and cut flos to pharmaceutical manufacturers, compounding pharmacies, and government medicinal cannabis programmes worldwide. The company also sells finished cannabinoid formulations (Bedromed sublingual spray and oromucosal drops) and partners to offer a 70% THC concentrate for compounding pharmacies.

Product overview

Bedrocan is an EU GMP-certified producer of standardised, pharmaceutical-grade medicinal cannabis. The core offering is a portfolio of cannabis Active Pharmaceutical Ingredients (APIs) — different chemovars with fixed THC:CBD ratios — sold as dried flower (flos) and as raw materials for pharmaceutical manufacturers and compounding pharmacies. The product portfolio includes: Bedrocan® (22% THC, flagship), Bedrocan® forte (25% THC), Bedropuur® (20% THC), Bedrolina® (14% CBD), Bedrobinol® (13.5% THC), Bediol® (balanced THC/CBD), Bedrolite® (high CBD), and Bedica® (indica-type). In 2026, the company launched Bedromed — a new line of standardised formulations (sublingual spray and oromucosal drops) derived from its cannabis APIs, bringing pharmaceutical-grade consistency into modern patient-friendly delivery formats. A new Becanex PIEX cannabis concentrate for compounding pharmacies is also planned for summer 2026.

Differentiator

Problem solved

Functional benefit

Brands

• Bedromed: Standardised cannabinoid-based formulations product line including sublingual spray and oromucosal drops with various THC:CBD ratios.
• Becanex PIEX
• Bedropuur
• Bedrolina
• Bedrocan
• Bedrocan forte

Products and services

• Bedrocan® The primary standardised cannabis chemovar (Cannabis sativa L. 'Afina') with 22% THC and <1% CBD. The flagship product of Bedrocan, used as a pharmaceutical API since 2003, with consistent cannabinoid and terpene profile batch to batch.
• Bedrocan® forte (25% THC) Enhanced version of the Bedrocan® chemovar with 25% THC (up from 22%), using the same Cannabis sativa L. 'Afina' genetics. Produced in the Danish EU-GMP facility with refined growing conditions. Complies with European Pharmacopoeia monograph.
• Bedropuur® High-THC chemovar (Cannabis sativa L. 'Harmina') with 20% THC and <1% CBD. Originally developed as a raw material for manufacturing high-THC extracts. Available in flos and cut flos forms.
• Bedrolina® High-CBD chemovar (Cannabis sativa L. 'Janna') with <1% THC and 14% CBD. Developed to supply CBD extracts and other CBD products. One of the most recent products in the portfolio.
• Bedrobinol® Standardised cannabis chemovar with approximately 13.5% THC and <1% CBD. One of the original cannabis products supplied to the Dutch Medicinal Cannabis Programme since 2003.
• Bediol® Balanced THC:CBD cannabis chemovar with approximately 6.3% THC and 8.8% CBD. One of the original products supplied to the Dutch Medicinal Cannabis Programme since 2003, also used in clinical studies such as the LUMC fibromyalgia pain study.
• Bedrolite® High-CBD cannabis chemovar with <1% THC and approximately 8.1% CBD. Used by compounding pharmacies for CBD oil preparations. Available from Dutch pharmacies including Transvaal Apotheek and MYCB1 Apotheek.
• Bedica® Indica-type cannabis chemovar with approximately 14.4% THC and <1% CBD. One of five cannabis strains available by prescription in the Netherlands.
• Bedromed spray Standardised cannabinoid-based formulation for sublingual administration, derived from Bedrocan® and Bedrolina® cannabis APIs. Part of the new Bedromed product line offering patient-friendly delivery formats with various THC:CBD ratios. Initial availability in Germany starting August 2026.
• Bedromed drops Standardised cannabinoid-based formulation for oromucosal administration, derived from Bedrocan® cannabis API. Part of the Bedromed product line. Multiple THC:CBD ratio options including THC-dominant and balanced formulations.
• Becanex PIEX Bedrocan 70% THC Concentrate Pharmaceutical-grade cannabis concentrate for compounding pharmacies, preserving the natural cannabinoid and terpene profile of Bedrocan flower. Jointly developed with Becanex using proprietary extraction method. Target availability summer 2026, first market Germany.

Quantifiable outcome

• Consistent cannabinoid and terpene profile across every batch
• +3 more outcomes

Named customers6 records

Segments5 records

Ideal customer profiles5 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration3 records

Feature5 records

Partnerships

Three partnerships are on record, tiered core.

• BecanexcoreStrategic or Co-development Partner · 19 May 2026Berlin-based extraction specialist Becanex has partnered with Bedrocan to launch Bedrocan flower as a pharmaceutical-grade 70% THC concentrate (Becanex PIEX Bedrocan 70% THC Concentrate) for compounding pharmacies. The proprietary extraction method preserves the natural cannabinoid and terpene profile of the original flower. Supply is planned to begin in summer 2026, with Germany as the first market, marking the beginning of a broader product collaboration between the two firms.
• Medios AGcoreChannel Partner/ Reseller/ Distributor · 20 January 2026Berlin-based Medios AG serves as Bedrocan's exclusive distribution partner for medicinal cannabis products across Germany, Spain, Belgium, Italy, and Austria. Initially covering production from Bedrocan's EU-GMP-certified Danish facility, with expansion planned from 2027. The partnership leverages Medios AG's existing pharmacy and wholesaler network, including the Cannaflos network in Germany, to streamline procurement for pharmacists who previously had to navigate a fragmented market of dozens of distributors.
• NovachemcoreChannel Partner/ Reseller/ DistributorAustralian distributor Novachem delivers Bedrocan's cannabis API products to pharmacies in 10-gram packages directly for patient use. Compounding pharmacies can order through Novachem's online portal (accessible only to registered pharmacies with an account). Novachem also handles new cannabis API products (Bedropuur® and Bedrolina®) grown at Bedrocan's Danish EU-GMP facility for the Australian market, available in 400 or 3,000 gram packaging.

Scale indicators7 records

Recent moves10 records

Expansion highlights6 records

Direct peers

• Demecan: German medicinal cannabis producer with EU-GMP-certified cultivation, competing directly with Bedrocan in the German pharmacy channel. Both supply standardised cannabis flos to German compounding pharmacies and wholesalers and are pursuing the same German regulatory framework.
• Cantourage: Berlin-based medicinal cannabis distributor and producer supplying German pharmacies, with a similar channel-partner-led model to Bedrocan/Medios AG. Competes in the same German pharmacy and compounding segment with comparable product positioning.
• MediPharm Labs: GMP-certified cannabis concentrate and API producer supplying pharmaceutical and wellness customers. Directly comparable as a pharma-grade cannabis API/extract supplier targeting similar drug-development and compounding pharmacy customers.
• GW Pharmaceuticals (Jazz Pharmaceuticals): Developer of Sativex and Epidiolex, the most established pharmaceutical-grade cannabis-derived medicines globally. Direct peer in pharmaceutical-grade cannabis standardisation, regulatory rigour, and prescriber/clinical channel.

Broad incumbents

• Aurora Cannabis: Canadian licensed producer with EU-GMP facilities supplying European medicinal cannabis markets. Competes in the same EU pharmacy channel as Bedrocan, with broader product portfolio and larger production scale.
• Canopy Growth Corporation: Canadian-headquartered cannabis producer with European medicinal cannabis operations. Broad incumbent with overlapping European medicinal cannabis distribution and pharmaceutical-channel relationships.
• OrganiGram Holdings: Canadian licensed producer with EU-GMP operations supplying the German and broader European medicinal cannabis market. Competes in the same standardised cannabis flos segment with established European distribution.
• Tilray Brands: Large Canadian cannabis producer with EU-GMP-certified operations and significant German and European medicinal cannabis distribution. Overlaps with Bedrocan in pharmaceutical-grade supply and the German pharmacy channel but operates at meaningfully larger scale and across adult-use and CPG.

Emerging players

• Little Green Pharma: Australian medicinal cannabis producer with EU-GMP capabilities and European expansion ambitions. Direct overlap with Bedrocan in standardised cannabis APIs and Australian market, smaller scale.
• Therismos: European medicinal cannabis distributor and processor supplying pharmacies in Germany, the UK, and other European markets. Comparable in channel model (specialised cannabis distribution into European pharmacies) to Bedrocan's relationship with Medios AG.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/BedrocanInfo

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Bedrocan